|
| Index | - | P/E | - | EPS (ttm) | -1.49 | Insider Own | 0.40% | Shs Outstand | 58.38M | Perf Week | -7.58% |
| Market Cap | 100.47M | Forward P/E | - | EPS next Y | -2.04 | Insider Trans | 322.60% | Shs Float | 51.56M | Perf Month | 27.08% |
| Income | -86.80M | PEG | - | EPS next Q | -0.51 | Inst Own | 76.70% | Short Float / Ratio | 5.69% / 9.75 | Perf Quarter | 40.77% |
| Sales | - | P/S | - | EPS this Y | -196.20% | Inst Trans | 0.94% | Short Interest | 2.93M | Perf Half Y | -39.20% |
| Book/sh | 3.46 | P/B | 0.53 | EPS next Y | -15.90% | ROA | -35.50% | Target Price | 10.33 | Perf Year | -84.79% |
| Cash/sh | 3.81 | P/C | 0.48 | EPS next 5Y | - | ROE | -37.00% | 52W Range | 0.75 - 13.01 | Perf YTD | 8.28% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -85.93% | Beta | - |
| Dividend % | - | Quick Ratio | 17.80 | Sales past 5Y | - | Gross Margin | - | 52W Low | 144.00% | ATR | 0.24 |
| Employees | 30 | Current Ratio | 17.80 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 53.79 | Volatility | 12.37% 14.32% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -3.20% | Profit Margin | - | Rel Volume | 1.33 | Prev Close | 1.71 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 300.71K | Price | 1.83 |
| Recom | 1.30 | SMA20 | -1.28% | SMA50 | 29.28% | SMA200 | -42.29% | Volume | 401,237 | Change | 7.02% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite